― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be Hosted Onsite on Sunday, December 7 ― CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare di ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsAlan Musso - CFOIain Fraser - SVP of Clinical DevelopmentAlex Sapir - CEO and PresidentMatthew Biegler - Managing DirectorTazeen Ahmad - Managing DirectorConference Call ParticipantsCorinne Johnson - Equity Research AnalystAndres Maldonado - Senior Biotechology AnalystKristen Kluska - Equity Research AnalystEdward Tenthoff - Biotech Equity Research AnalystJoseph P. Schwartz - Senior Research AnalystLu ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsAlan Musso - CFOIain Fraser - SVP of Clinical DevelopmentAlex Sapir - CEO and PresidentMatthew Biegler - Managing DirectorTazeen Ahmad - Managing DirectorConference Call ParticipantsCorinne Johnson - Equity Research AnalystAndres Maldonado - Senior Biotechology AnalystKristen Kluska - Equity Research AnalystEdward Tenthoff - Biotech Equity Research AnalystJoseph P. Schwartz - Senior Research AnalystLu ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Speaker4Good morning and welcome to the Fulcrum Therapeutics third quarter 2025 financial results and business update conference call. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the investor section of Fulcrum's website at www.fulcrumtx.com and is being recorded. Please be reminded that remarks during this call may contain forward-looking statements withi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other ...

Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 ― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end ― ― Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2 ...

― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end ― ― Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a c ...

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and p ...

― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it will present preclinical data for FTX-6274, an oral embryonic ectoderm development, or EED, inhibitor, in castration-r ...

CAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an in ...